July 1st will be a big day for me and for a lot of Medicare Part D beneficiaries.

Both are exciting, though for very different reasons.

But the Medicare piece deserves a closer look. Part D still does not cover GLP-1s when they’re used solely for weight loss, and this new $50 pathway sits outside the normal Part D benefit.

In other words, the headline is simple. The policy is not.

In this article, I’ll give a quick background on Medicare’s long-standing exclusion of weight-loss medications, explain the BALANCE and Bridge models, and break down what this means for patients, physicians, and the health system.

For two decades, Medicare Part D has prohibited coverage of weight-loss drugs, largely because of legitimate safety concerns at the time (think fen-phen). That policy was cemented in the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

Fast forward 20+ years, and we now have remarkably effective and safe GLP-1s for patients with obesity, and for patients with overweight + one weight-related comorbidity.

Over the past couple of years—spanning two administrations—coverage of GLP-1s for weight loss has been controversial:

The key takeaway: the Biden administration proposed Medicare coverage for GLP-1s for weight loss; the Trump administration initially shut that down, then later rolled out its own approach via the Medicare GLP-1 Bridge and BALANCE.

To understand where Medicare GLP-1 coverage is headed, you need to understand two programs: Bridge and BALANCE.

For models like these, it helps to ask a simple question: Who actually benefits?

On paper, Bridge is a win. Medicare beneficiaries get access to GLP-1s for $50 per fill, CMS gets to say it is expanding access, and manufacturers get more patients on therapy. Physicians, also, get another option for obesity care. But when you look closer, the “win” is a lot less clear.

Patients get the most obvious short-term benefit.

For Medicare beneficiaries who have been priced out of GLP-1s for weight loss, $50 per fill is a deal. KFF polling has shown that nearly half of adults who have taken GLP-1s say the medications were difficult to afford. That tracks with what many of us see in practice, that these drugs work, but access is inconsistent and often depends on coverage luck.

While Bridge will help, it’s only temporary. The program runs through the end of 2027, and the fills happen outside Medicare Part D. That means the $50 payments do not count toward a patient’s Part D deductible or out-of-pocket cap. Low-income beneficiaries may also face higher costs than they would under normal Part D protections.

GLP-1s are not short-term medications for most patients. If access disappears after 2027, patients will likely stop therapy, regain weight, and end up back where they started. This is an access vs stability issue.

For physicians, the clinical case for GLP-1s is getting easier but the coverage pathway is getting harder. Bridge adds another prior authorization process and another set of coverage rules. We now have to figure out whether a patient’s GLP-1 should go through actual Part D, Bridge, or neither. Some indications stay in Part D. Others move through Bridge. Some patients may qualify for one product under one pathway and another product under a different one.

This will create more pharmacy confusion, more inbox messages, and more time spent explaining insurance rules instead of practicing medicine.

There are also oversight concerns. This JAMA piece notes that Bridge prescriptions may come from clinicians who are not enrolled in Medicare. In a GLP-1 market already shaped by online prescribing and cash-pay clinics, CMS will need strong guardrails around eligibility, monitoring, and follow-up.

My take on all these models—negotiated prices, TrumpRx, compounded meds, and direct-to-consumer options—is that there’s no single GLP-1 price. There’s the list price, net price, negotiated Medicare price, Bridge price, Medicaid rebate price, cash-pay price, DTC platform price, and the patient’s copay. Everyone negotiates around a different number.

Patients want affordability. I, as a physician, want a simpler prescribing pathway. Plans want to avoid open-ended risk. CMS wants lower spending (see graphic below for how much CMS is spending). Manufacturers want broader access without giving up too much pricing power.

Right now, everyone gets part of what they want, and patients still end up stuck in the middle of the complexity. I’m not sure that changes without the incentives changing too.

In summary, Medicare’s GLP-1 Bridge will meaningfully lower the cash barrier for a lot of Part D beneficiaries, but it doesn’t solve the bigger problem of stable, integrated coverage. Because Bridge fills sit outside Part D, patients can still get stuck with confusing rules, extra admin friction, and payments that don’t count toward the protections they assume they’re earning. For us physicians, it adds yet another prescribing pathway to navigate, while CMS, plans, and manufacturers keep negotiating around different “prices” that patients never really see. If GLP-1s are going to be treated like chronic therapies, we need a model that prioritizes durability and simplicity—not just a temporary discount.